InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 267394

Sunday, 06/26/2016 10:07:18 PM

Sunday, June 26, 2016 10:07:18 PM

Post# of 345732
I disagree 100% carboat. No RS is a coming when all it takes is one PR about the FULL list of collaborations.

Just ask Janssen and Bluebird Bio or Pfizer even.......

The question is when all the puzzle pieces continue to pile up, and we see even bigger and better Big Pharmas than BMS... what does one do?

C'mon... landscapers are not supposed to figure this out .. but its becoming more obvious by the day

Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes

Review and Case Studies

Jennifer L. Rojko1?
Mark G. Evans2
Shari A. Price1
Bora Han2
Gary Waine3
Mark DeWitte4
Jill Haynes3
Bruce Freimark5
Pauline Martin6
James T. Raymond1
Winston Evering2
Marlon C. Rebelatto7
Emanuel Schenck7
Christopher Horvath8

1Charles River Pathology Associates, Frederick, Maryland, USA
2Pfizer, Inc, San Diego, California, USA
3CSL Limited, Parkville, Melbourne, Australia
4CSL Behring, King of Prussia, Pennsylvania, USA
5Peregrine Pharmaceuticals, Inc, Tustin, California, USA
6Janssen, Malvern, Pennsylvania, USA
7MedImmune, Gaithersburg, Maryland, USA
8bluebird bio, Cambridge, Massachusetts, USA

http://tpx.sagepub.com/content/42/4/725.abstract


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News